AstraZeneca investors raise concerns over mega-merger talks

Investors in AstraZeneca are expressing apprehension about the company's discussions regarding a massive merger with Bristol Myers Squibb, potentially valued at $400 billion. Key concerns include the looming expiration of key patents, which could lead to a "patent cliff," and the potential antitrust hurdles that could complicate the deal. This merger talks' fallout could significantly impact AstraZeneca's future revenue streams and market position, making the concerns from shareholders quite valid and important to consider.